Abstract

Cardiovascular disease is one of the deadliest diseases in the world. Nowadays, alongside the developments of various medical therapeutic strategies, there is a decreasing trend of cardiovascular mortality. However, this reduction is not adequate and needs to be supported by cardiovascular prevention approaches. Statins and aspirin are two of cardiovascular drugs that are believed to be beneficial in cardiovascular prevention. Their magnificent efficacies in the secondary prevention setting lead them to be used in the primary prevention. However, some safety issues associated with the drugs should be considered. For that reason, based on previous trials and studies, some recommendations regarding the efficacy-safety issues are developed.

Highlights

  • For many years, Cardiovascular Disease (CVD) has become a global burden and caused limitations in daily activities

  • Statins and aspirin are widely used as secondary prevention modalities in atherosclerotic cardiovascular diseases, especially coronary artery disease.[6]

  • A non-steroidal anti-inflammatory drug, which acts as an anti-platelet in cardiovascular disease management, plays a role in secondary prevention of atherosclerotic CVD

Read more

Summary

Henry Sutanto

Alongside the developments of various medical therapeutic strategies, there is a decreasing trend of cardiovascular mortality. This reduction is not adequate and needs to be supported by cardiovascular prevention approaches. Statins and aspirin are two of cardiovascular drugs that are believed to be beneficial in cardiovascular prevention. Their magnificent efficacies in the secondary prevention setting lead them to be used in the primary prevention. Some safety issues associated with the drugs should be considered. For that reason, based on previous trials and studies, some recommendations regarding the efficacy-safety issues are developed

Laporan Kasus
Introduction
Overview of pharmacological aspects of statins and aspirin
Roles of statins and aspirin in ASCVD management
Cardiovascular risk assessments in ASCVD
Statins in primary prevention of ASCVD
Aspirin in primary prevention of ASCVD
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.